- NEWS AND VIEWS
- Correction 08 February 2021
Mutation alters chromatin changes during injury response to drive cancer
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature 590, 557-558 (2021)
Updates & Corrections
Correction 08 February 2021: This article incorrectly described KRAS as a type of enzyme termed a kinase. It is a GTPase.
Giroux, V. & Rustgi, A. K. Nature Rev. Cancer 17, 594–604 (2017).
Alonso-Curbelo, D. et al. Nature 590, 642–648 (2021).
Guerra, C. et al. Cancer Cell 11, 291–302 (2007).
Habbe, N. et al. Proc. Natl Acad. Sci. USA 105, 18913–18918 (2008).
Storz, P. Nature Rev. Gastroenterol. Hepatol. 14, 296–304, (2017).
Li, Y. et al. Nature Cancer 2, 49–65 (2021).
Whyte, W. A. et al. Cell 153, 307–319 (2013).
Mazur, P. K. et al. Nature Med. 21, 1163–1171 (2015).
Gilan, O. et al. Science 368, 387–394 (2020).
Beyer, G., Habtezion, A., Werner, J., Lerch, M. M. & Mayerle, J. Lancet 396, 499–512 (2020).
M.A.D. has been a member of advisory boards for GlaxoSmithKline, CTx CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. The Dawson lab receives research funding from CTx CRC.